|
Mr. Engelhorn is an active early-stage private investor in technology and life sciences companies. In 1987, he co-founded NOVEX, a biotechnology research tools company. During his tenure at NOVEX he held senior management positions including Vice President R&D, Executive Vice President Corporate Development, President and CEO. NOVEX achieved $35M in annual sales prior to its merger with Invitrogen in 1999. Prior to founding NOVEX, he held a variety of positions in product development, product support, marketing and field sales at Bio-Rad Laboratories. He began his career at the University of California, San Diego, as a Staff Research Associate in the Metabolic Disease Division of the UCSD medical school. He has multiple publications in chromatography and electrophoresis and holds a number of patents, including patents on NOVEX's key technologies. Mr. Engelhorn sits on the boards of three private early-stage technology companies. | 